EQL PHARMA AB (7JK) — Cash Flow Quality Index
Latest as of December 2025:
1.37x
EQL PHARMA AB (7JK) has a Cash Flow Quality Index of 1.37x as of December 2025. Operating cash flow of €13.44 Million exceeds net income of €9.79 Million, indicating high earnings quality where cash backs reported profits. Explore 7JK cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
1.37x
Operating CF / Net Income
Operating Cash Flow
€13.44 Million
EUR
Net Income
€9.79 Million
EUR
Data as of
Dec 2025
Most recent filing
EQL PHARMA AB Cash Flow Quality Index (2022–2026)
Historical Cash Flow Quality Index for EQL PHARMA AB across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 7JK cash generation efficiency.
Annual Cash Flow Quality Index for EQL PHARMA AB (2022–2026)
Year-by-year earnings quality comparison for EQL PHARMA AB.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2026 | 2.26x | €28.36 Million | €12.54 Million | ▲ +495.7% |
| 2025 | -0.57x | €-24.65 Million | €43.12 Million | ▼ -13.5% |
| 2024 | -0.50x | €-11.44 Million | €22.70 Million | ▼ -156.4% |
| 2023 | 0.89x | €27.62 Million | €30.92 Million | ▼ -32.6% |
| 2022 | 1.33x | €41.83 Million | €31.55 Million | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.